For the year ending 2025-12-31, RLAY had -$41,052K decrease in cash & cash equivalents over the period. -$235,865K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -276,479 |
| Depreciation expense | 3,557 |
| Stock compensation expense | 62,419 |
| Impairment of intangible asset | 2,300 |
| Loss on disposal of property and equipment | -1,003 |
| Net amortization of premiums and discounts on investments | 4,949 |
| Prepaid expenses and other current assets | -1,612 |
| Operating lease assets and liabilities, net | 4,272 |
| Accounts payable and accrued expenses | -11,440 |
| Deferred revenue | -7,679 |
| Other liabilities | -1,527 |
| Net cash used in operating activities | -235,455 |
| Purchases of property and equipment | 410 |
| Purchases of investments | 122,971 |
| Proceeds from maturities and sales of investments | 316,180 |
| Net cash provided by (used in) investing activities | 192,799 |
| Proceeds from issuance of common stock through exercise of stock options | 524 |
| Proceeds from issuance of common stock via employee stock purchase plan | 1,080 |
| Net cash provided by financing activities | 1,604 |
| Net decrease in cash, cash equivalents, and restricted cash | -41,052 |
| Cash, cash equivalents and restricted cash at beginning of period | 126,406 |
| Cash, cash equivalents and restricted cash at end of period | 85,354 |
Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY)